Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQS 168

Next Previous
Search
Drug Profile

TQS 168

Alternative Names: TQS-168

Latest Information Update: 28 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tranquis Therapeutics
  • Class Anti-inflammatories; Antidementias; Small molecules
  • Mechanism of Action Myeloid cell modulators; Peroxisome proliferator-activated receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Neurodegenerative disorders

Most Recent Events

  • 28 Sep 2024 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis(In volunteers) in United Kingdom (PO)
  • 19 Sep 2022 Phase-I clinical trials in Amyotrophic lateral sclerosis in USA (PO) (Tranquis Therapeutics website, September 2022)
  • 01 Sep 2022 TQS 168 is still in phase I trials for Amyotrophic lateral sclerosis in the United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top